Global Access Program News Today

This is an opportune time to reflect on the strides made in healthcare across the continent.

Nearly half the global population doesn't have access to the most basic diagnostics. To hit the UN's 2030 goal of health care for all, that must change.

Cepheids Xpert MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at Cepheids cost of $7.97 for eligible buyers

Danaher Corporation announced that it will reduce the price of its Cepheids Xpert MTB/RIF Ultra diagnostic test cartridges for tuberculosis by 20% in high-TB-burden countries. The price will be decreased from $9.98 to $7.97 per test to support greater access to high-quality TB testing.

?        Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die...

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 women

A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Devices sectors from 9th-13th May ...

Roche plans to extend prophylactic treatment for patients with haemophilia and provide testing for HIV and TB in developing countries.

Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Global Fund to Fight AIDS, Tuberculosis and Malaria are joining forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB). About 2 billion ...

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure